Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Nausea and Vomiting Caused by Chemothera...
Phase PHASE2
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy. It will also learn about the safety and influence on gastrointestinal function of auricular point stimulation plus dexamethasone. The main questions it aims to answer are: Can auricular point stimulation plus dexamethasone effectively prevent or suppress nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen? Can auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions caused by excessive use of antiemetic drugs? Participants will: Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Other: Auricular point stimulation plus dexamethasone — On the day of chemotherapy (Day 1): Within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone. From the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5): Stimulate each acupoint once in the morning, noon, and evening, for 5 minutes each time. If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure. Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.

Primary Outcomes

  • Proportion of patients experiencing nausea as assessed by NIC-CTC AE4.0 (from the day of chemotherapy (Day 1) until the end of Day 5)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-25
Completion: 2026-11
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Principal Investigators:
  • Juan Wang (STUDY_CHAIR) - Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Juan Wang
8617816190946
wangjuan.happy@hotmail.com
Juan Wang
8617816190946
wangjuan.happy@hotmail.com
Second Affiliated Hospital of Zhejiang University School of Medicine
Interventions
  • Other: Auricular point stimulation plus dexamethasone — On the day of chemotherapy (Day 1): Within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone. From the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5): Stimulate each acupoint once in the morning, noon, and evening, for 5 minutes each time. If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure. Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.
Study Locations (1 sites)
Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Eligibility Criteria
Inclusion Criteria: Patients must meet the following inclusion criteria for the study: * Age ≥ 18 years and ≤ 85 years * After a radical mastectomy, further postoperative adjuvant chemotherapy with docetaxel combined with cyclophosphamide regimen is required. * ECOG performance status score of 0-2. * Normal hematological function (platelet count \> 80×10⁹/L; white blood cell count \> 3×10⁹/L; neutrophil count \> 1.5×10⁹/L). * Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN. * No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L. * Child-Pugh classification of liver function is Grade A. * Serum creatinine \< ULN, or calculated creatinine clearance rate \> 50ml/min. Exclusion Criteria: Patients who meet any of the following criteria will be excluded from the study: * Local inflammation or infection of the auricle * Bleeding tendency or coagulation disorders * Severe ascites * Gastrointestinal obstruction * Hypertensive crisis or hypertensive encephalopathy * Severe uncontrolled systemic complications such as infection or diabetes mellitus * Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment * A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke) * Hypersensitivity to any drugs used in the study * Pregnant or lactating women * Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications * Inability or unwillingness to comply with the study protocol
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The MILES Study is a longitudinal, mixed-methods investigation of urinary biomarkers, energy balance, and lifestyle modifications in diverse women during early breast cancer treatment. The study's overarching goal is to assess dietary quality and physical activity changes over time using reliable, scalable tools suitable for clinical or population settings, supporting newly diagnosed patients in adopting and maintaining healthy behaviors through treatment and survivorship.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Survey completion — Surveys will evaluate dietary quality, physical activity, tobacco use, demographic and socio-economic/occupation factors and perspectives about participation in biomedical/biospecimen research.
  • Other: Urine specimen banking — The study team will collect the first urine of the day from these volunteers on the same day that they complete the lifestyle questionnaires. The urine will be used for metabolomics testing via Nuclear Magnetic Resonance (NMR) spectroscopy and will be correlated with the survey data.
  • Other: Qualitative interviews — After the survey and urine specimen have been received, participants will be scheduled for online or in-person semi-structured interviews. Semi-structured interviews will be conducted at baseline (either before or after surgery, but not both for the same individual) and at follow up.

Primary Outcomes

  • Change in lifestyle behavior score based (Baseline, 1 month, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-20
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Abramson Cancer Center at Penn Medicine
Collaborators: Penn State University
Contact Information
Study Contact:
Julia Lewandowski
215-913-2031
Julia.lewandowski@pennmedicine.upenn.edu
Margaret Pichardo
margaret.pichardo@pennmedicine.upenn.edu
John Plastaras, MD, PhD
855-216-0098
PennCancerTrials@emergingmed.com
Abamson Cancer Center of the University of Pennsylvania
Interventions
  • Other: Survey completion — Surveys will evaluate dietary quality, physical activity, tobacco use, demographic and socio-economic/occupation factors and perspectives about participation in biomedical/biospecimen research.
  • Other: Urine specimen banking — The study team will collect the first urine of the day from these volunteers on the same day that they complete the lifestyle questionnaires. The urine will be used for metabolomics testing via Nuclear Magnetic Resonance (NMR) spectroscopy and will be correlated with the survey data.
  • Other: Qualitative interviews — After the survey and urine specimen have been received, participants will be scheduled for online or in-person semi-structured interviews. Semi-structured interviews will be conducted at baseline (either before or after surgery, but not both for the same individual) and at follow up.
Study Locations (1 sites)
Abamson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania 19104 United States
Eligibility Criteria
Inclusion Criteria: * Adult women (age 18 years or older) * Able to read English or Spanish * Newly diagnosed with primary stage 0, I, II, or III breast cancer * Pathological diagnosis within the previous 60 days * Scheduled to have surgery with a Penn Medicine surgeon Exclusion Criteria: * Women age less than 18 years * Women without a new primary breast cancer diagnosis * Women who are pregnant
Conditions HER2-positive Breast Cancer
Phase PHASE2
Enrollment 124
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study is a response-adapted, multicenter, interventional trial enrolling patients with HER2-positive early or locally advanced breast cancer. All enrolled patients will first receive 2 cycles of standard neoadjuvant THP regimen, consisting of a taxane, trastuzumab, and pertuzumab. After the initial 2-cycle treatment, tumor response will be evaluated by radiologic imaging and patient-derived organoid (PDO) drug sensitivity testing. Patients with an inadequate response to THP are defined as those with \<50% tumor size reduction on imaging, or failure to reach the PDO sensitivity threshold (\<80% tumor cell killing for HER2+/HR- tumors; \<60% for HER2+/HR+ tumors). These non-responders will switch to receive 4 cycles of trastuzumab rezetecan (SHR-A1811), a novel HER2-targeted antibody-drug conjugate (ADC). Patients with a favorable response (≥50% tumor reduction or meeting the PDO threshold) will continue with an additional 4 cycles of THP. The primary objective is to evaluate the pathologic complete response (pCR) rate in THP non-responders after switching to trastuzumab rezetecan. Secondary objectives include objective response rate (ORR), event-free survival (EFS), overall survival (OS), 3-year invasive disease-free survival (iDFS), and safety profiles of both treatment strategies. Outcomes in patients who continue THP will be described for exploratory purposes. A total of 124 patients will be enrolled. This response-adapted, individualized strategy aims to provide an effective option for HER2-positive breast cancer patients with an inadequate early response to conventional THP neoadjuvant therapy.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: THP Regimen (Taxane + Trastuzumab + Pertuzumab) — Neoadjuvant combination therapy consisting of a taxane, trastuzumab, and pertuzumab. Administered as initial treatment to all patients, and continued for responders.
  • Drug: Trastuzumab Rezetecan (SHR-A1811) — HER2-targeted antibody-drug conjugate (ADC). Administered to patients with inadequate response to initial THP therapy.

Primary Outcomes

  • Pathologic Complete Response (tpCR) Rate (Perioperative)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-03-24
Completion: 2031-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Soochow University
Principal Investigators:
  • Zhaoji Guo (STUDY_CHAIR) - The First Affiliated Hospital of Soochow University
Contact Information
Study Contact:
Hao Zhou
+8613862097709
dlou515@163.com
Interventions
  • Drug: THP Regimen (Taxane + Trastuzumab + Pertuzumab) — Neoadjuvant combination therapy consisting of a taxane, trastuzumab, and pertuzumab. Administered as initial treatment to all patients, and continued for responders.
  • Drug: Trastuzumab Rezetecan (SHR-A1811) — HER2-targeted antibody-drug conjugate (ADC). Administered to patients with inadequate response to initial THP therapy.
Study Locations (1 sites)
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006 China
Eligibility Criteria
Inclusion Criteria: * 1.Age ≥18 years. For premenopausal and perimenopausal patients, a negative pregnancy test is required, and the patient must agree to use effective contraception during treatment. * 2.Pathologically confirmed invasive breast cancer, stage II-III according to the 8th edition of the American Joint Committee on Cancer (AJCC) TNM staging system, with HER2-positive disease defined as: immunohistochemistry (IHC) 3+; or IHC 2+ with confirmed HER2 gene amplification by fluorescence in situ hybridization (FISH). * 3.At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. * 4.No prior chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy for breast cancer. * 5.Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * 6.Ability to understand and provide written informed consent. * 7.Adequate organ function as evidenced by the following laboratory values: * Hemoglobin ≥90 g/L * White blood cell count ≥3.5×10⁹/L * Platelet count ≥100×10⁹/L * Neutrophil count ≥1.5×10⁹/L * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤3× upper limit of normal (ULN) * Total bilirubin ≤1.5×ULN * Serum creatinine ≤1.5×ULN * 8.No evidence of myocardial ischemia on electrocardiogram (ECG); New York Heart Association (NYHA) functional class I; left ventricular ejection fraction (LVEF) ≥55% on echocardiogram; cardiac biomarkers (cardiac troponin I \[cTnI\] and B-type natriuretic peptide \[BNP\]) within normal limits. * 9.All required baseline laboratory and radiologic examinations completed prior to neoadjuvant therapy. * 10.No dysphagia. * 11.Availability of complete clinical data. Exclusion Criteria: * 1.Male breast cancer or inflammatory breast cancer. * 2.Metastatic breast cancer (Stage IV). * 3.Presence of other concurrent malignancies or history of malignancy other than breast cancer within the past 5 years, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. * 4.Receipt of any other concurrent anti-cancer therapy or participation in another clinical trial. * 5.Presence of severe non-malignant disease that would compromise patient compliance or place the patient at unacceptable risk. * 6.Major surgical procedure within 4 weeks prior to initiation of study treatment, or anticipated need for major surgery during the study period. * 7.Receipt of radiotherapy, chemotherapy, molecular targeted therapy, endocrine therapy, or major breast surgery for breast cancer within 4 weeks prior to study treatment; current or prior use of HER2-targeted monoclonal antibodies, HER2-targeted antibody-drug conjugates (ADCs), or tyrosine kinase inhibitors (TKIs). * 8.History of hypersensitivity or contraindication to any component of the study drugs. * 9.Poorly controlled cardiac symptoms or diseases, including: New York Heart Association (NYHA) Class II or higher heart failure; unstable angina; myocardial infarction within 1 year; clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention. Dementia, intellectual disability, or any psychiatric disorder that impairs the ability to understand the informed consent form.
Conditions Chemotherapy-Induced Amenorrhea
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Chemotherapy for cancer, due to its gonadotoxicity, can lead to impaired female fertility, resulting in the occurrence of transient or prolonged chemo-induced amenorrhea (CIA). According to recent data from the National Cancer Institute, 11.9% of women under the age of 40 diagnosed with cancer have been offered a fertility evaluation within five years of diagnosis. Predicting the risk and especially the duration of the CIA remains difficult. Known factors predicting a rapid return of menstruation are a young age at diagnosis, a low gonadotoxic treatment (absence of alkylating agents) and a high pre-chemotherapy blood level of AMH reflecting a large pool of growing follicles. A body mass index (BMI) ≥ 25 kg / m² could also be a positive predictor, but this remains debated. The objective of this project is to assess the impact of metabolism and energy reserves, physical activity and the chronotype on the recovery of ovarian function in patients with breast cancer who have developed CIA

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Concentration of IL-6 levels at the end of chemotherapy (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-02-24
Completion: 2026-06
Eligibility
Age: 25 Years – 35 Years
Sex: FEMALE
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Lille
Principal Investigators:
  • Pascal PIGNY, MD,PhD (PRINCIPAL_INVESTIGATOR) - University Hospital, Lille
Contact Information
Study Contact:
Pascal PIGNY, MD,PhD
0320445962
pascal.pigny@chru-lille.fr
Interventions
N/A
Study Locations (1 sites)
Hop Jeanne de Flandre Chu Lille, Lille, France
Eligibility Criteria
Inclusion Criteria: * Women with a chemotherapy-induced (CIA) amenorrhea who asked for post-cancer fertility follow-up at the University Hospital of Lille, France. * Women between 25 to 35 years age at inclusion * Chemotherapy protocol: FEC 100 (3 cycles) + docetaxel (3 cycles Exclusion Criteria: * Women without CIA * Women who refuse to participate in the study * Women older than 35 years at inclusion * Women who received another chemotherapy protocol
Conditions HER2 Positive Breast Cancer, Pyrotinib T...
Phase PHASE2, PHASE3
Enrollment 964
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, randomized controlled clinical study to evaluate the effect of using intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment. Pyrotinib is a small molecule tyrosine kinase inhibitor that can irreversibly inhibit HER1, HER2, and HER4.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Drug: pyrotinib — Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.

Primary Outcomes

  • medication adherence at 1-year (1-year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2024-04-30
Completion: 2027-04-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 964 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigators:
  • Jiani Wang, M.D. (PRINCIPAL_INVESTIGATOR) - National Cancer Center Cancer Hospital
Contact Information
Study Contact:
Jiani Wang, M.D.
86010877-88120
ncc_wangjiani@126.com
Fei Ma
86-10-87788060
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: pyrotinib — Intelligent patient management system on medication adherence of HER2 positive breast cancer patients receiving pyrotinib treatment.
Study Locations (1 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥ 18 years. * Histologically confirmed HER2-positive breast cancer (IHC 3+ or IHC 2+ with ISH+). * Patients expected to receive pyrotinib-containing regimens for neoadjuvant therapy or metastatic/unresectable breast cancer. ·≤1 prior line of anti-HER2 therapy during the recurrent/metastatic stage. * Ability to operate a mobile phone and read independently. * Deemed psychologically and physically suitable for participation by the investigator. Exclusion Criteria: * History of cognitive impairment. * Severe visual or auditory impairments. * Prior use of pyrotinib. * Pregnancy, lactation, or intention to conceive. * Ineffective cognitive-behavioral interventions within the past year. * Participation in other clinical trials within 1 month prior to screening. * Investigator judgment of unsuitability due to psychological or physical conditions.
Conditions Early Breast Cancer, Hormone Receptor Po...
Phase Not Applicable
Enrollment 319
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Around 90% of breast cancer patients are diagnosed at an early stage and approximately 70% are hormone receptor-positive and HER2-negative (HR+/HER2-). Despite advancements in adjuvant endocrine therapy, 20-30% of early-stage breast cancer patients relapse within the first decade post-surgery. A recent clinically meaningful therapeutic option for these patients has been cyclin-dependent kinases 4/6 inhibitors (CDK4/6 inhibitors). Abemaciclib and ribociclib were assessed in the adjuvant setting, both showing improvement in invasive disease-free survival (IDFS). Abemaciclib has been approved by the FDA and EMA for HR+/HER2- early breast cancer at high risk of disease recurrence and is the first addition to the Slovenian treatment regimen in routine clinical practice. Poor medication adherence can directly affect the effectiveness of treatment for early HR+/HER2- breast cancer. While adherence data in patients treated with aromatase inhibitors are available, the adherence rate in patients with early HR+/HER2- breast cancer taking abemaciclib remains unclear. In this study, investigators hypothesize that patients receiving abemaciclib in combination with aromatase inhibitors will have lower medication adherence and higher discontinuation rates compared to those receiving aromatase inhibitors alone. It is expected that patients with better quality of life, better cognitive functioning, and a more positive attitude toward their therapy will demonstrate higher medication adherence rates. Adherence may also be influenced by additional factors, such as age and prior treatments.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Medication adherence (Proportion of Days Covered, PDC) at Month 3 (Month 3 after treatment initiation)
  • Medication adherence (Proportion of Days Covered, PDC) at Month 6 (Month 6 after treatment initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-01-05
Completion: 2027-03-01
Eligibility
Age: 18 Years – 99 Years
Sex: FEMALE
Volunteers: false
Enrollment: 319 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Oncology Ljubljana
Collaborators: University of Ljubljana
Principal Investigators:
  • Erika Matos, PhD (PRINCIPAL_INVESTIGATOR) - Institute of Oncology Ljubljana, Slovenia
Contact Information
Study Contact:
Erika Matos, PhD
00386 1 5879 715
ematos@onko-i.si
Cvetka Grašič Kuhar, PhD
00386 1 5879 090
cgrasic@onko-i.si
Erika Matos, MD
0038615879715
ematos@onko-i.si
Institute of Oncology Ljubljana
Interventions
N/A
Study Locations (1 sites)
Institute of Oncology Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Female, * Early HR+/HER-2- BC, * Patient is receiving adjuvant therapy with an aromatase inhibitor (letrozole, anastrozole or exemestane), with or without a CDK4/6 inhibitor abemaciclib, for no more than 18 months, * Treatment of BC is being conducted at OIL, * Patient has mandatory health insurance through Health Insurance Institute of Slovenia, * Patient understands Slovenian language, and * Patient agrees to participate in the study and provides written informed consent. Exclusion Criteria: * Metastatic HR+/HER2-negative breast cancer * Previous treatment for breast cancer with an aromatase inhibitor, with or without a CDK4/6 inhibitor, for early breast cancer prior to the current adjuvant treatment line
Conditions HER2-positive Breast Cancer
Phase PHASE2, PHASE3
Enrollment 650
Locations 206 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to assess the efficacy and safety of RO7771950 in combination with trastuzumab and capecitabine, compared to tucatinib in combination with trastuzumab and capecitabine.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: RO7771950 — Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID).
  • Drug: Tucatinib — Participants will receive a dose of tucatinib PO BID.
  • Drug: Trastuzumab — Participants will receive trastuzumab in accordance with local prescribing information, either through intravenous (IV) or subcutaneously (SC).
  • Drug: Capecitabine — Participants will receive capecitabine according to local prescribing information. Capecitabine will be administered PO BID.

Primary Outcomes

  • Progression-free Survival (PFS) as Determined by Blinded Independent Central Review (BICR) (Approximately 35 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2026-05-21
Completion: 2032-09-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 650 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: WO46069 https://forpatients.roche.com/ No attachments to email below.
888-662-6728 (U.S. only)
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: RO7771950 — Participants will receive one of two doses of RO7771950 orally (PO) twice a day (BID).
  • Drug: Tucatinib — Participants will receive a dose of tucatinib PO BID.
  • Drug: Trastuzumab — Participants will receive trastuzumab in accordance with local prescribing information, either through intravenous (IV) or subcutaneously (SC).
  • Drug: Capecitabine — Participants will receive capecitabine according to local prescribing information. Capecitabine will be administered PO BID.
Study Locations (206 sites)
Clearview Cancer Institute, Huntsville, Alabama 35805 United States
Banner Health MD Anderson AZ, Gilbert, Arizona 85234 United States
UCSF Helen Diller Family CCC, San Francisco, California 94158 United States
Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut 06360 United States
Astera Cancer Care East Brunswick, East Brunswick, New Jersey 08816 United States
New York Oncology Hematology, P.C., Albany, New York 12206 United States
New York Cancer and Blood Specialists, Shirley, New York 11967 United States
Stony Brook Univ Cancer Ctr, Stony Brook, New York 11794 United States
Montefiore Einstein Cancer Center, The Bronx, New York 10461 United States
The West Clinic, PC dba West Cancer Center, Germantown, Tennessee 38138 United States
Eligibility Criteria
Inclusion Criteria: * Pathologically documented locally advanced inoperable (LAI) or metastatic breast cancer (MBC) with confirmed HER2-positive status by central laboratory. * Measurable disease as per by RECIST v1.1 in stage 1. Non-measurable disease allowed in stage 2. * Previously treated (stable or progressive) or previously untreated CNS metastases, or leptomeningeal metastases. * At least one prior line of anti-HER2-based therapy for LAI or metastatic disease. * Prior anti-HER2 antibody-drug conjugate (ADC), such as trastuzumab-deruxtecan (T-DXd) or trastuzumab emtansine (T-DM1), in any treatment setting. Participants without prior ADC therapy may only be enrolled if approved standard-of-care (SOC) anti-HER2 ADC is not locally accessible at screening, or if there is a prospectively documented clinical contraindication. * Prior tyrosine kinase inhibitor (TKI) in the (neo)adjuvant setting provided completion is \> 12 months ahead of LAI occurrence. Prior treatment with TKIs for LAI/MBC is not permitted. * Has protocol-defined adequate organ and bone marrow function. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Baseline left ventricular ejection fraction (LVEF) ≥ 50%. Exclusion Criteria: * Concurrent anti-cancer treatment, or treatment with investigational therapy within 28 days prior to initiation of study treatment. * Known active/untreated hepatitis B or C or chronic liver disease. * Clinically significant cardiovascular disease or risk, including heart failure (New York Heart Association (NYHA) ≥ II), ischemic heart disease or recent coronary events/interventions, clinically significant arrhythmias or electrocardiogram (ECG) abnormalities, QT prolongation or risk of ventricular dysrhythmias, poorly controlled hypertension, peripheral arterial disease, dilated cardiomyopathy, or unstable angina. * Clinically significant electrolyte abnormalities (e.g., hypokalemia, hypomagnesemia, hypocalcemia), or family history of sudden unexplained death or long QT syndrome. * Concomitant use of any drug or herbal medicine known to strongly inhibit or induce CYP3A4 or CYP2C8 activity, oral coumarin-derivative anticoagulants.
Conditions Breast Cancer
Phase PHASE3
Enrollment 640
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: D-0502 — * Dosage form: Tablet * Administration route: Oral, once a day
  • Drug: Fulvestrant — * Dosage form: Injection * Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose

Primary Outcomes

  • Progression free survival (PFS) assessed by Independent Review Committee (IRC) (From enrollment to the end of treatment, up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-09-15
Completion: 2028-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 640 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: InventisBio Co., Ltd
Principal Investigators:
  • Binghe Xu, MD (PRINCIPAL_INVESTIGATOR) - Cancer Hospital
  • Qingyuan Zhang, MD (PRINCIPAL_INVESTIGATOR) - Harbin
Contact Information
Study Contact:
Yuting Li
8615821378026
yuting.li@inventisbio.com
Binghe Xu
8613501028690
xubinghe@medmail.com.cn
Cancer Hospital Chinese Academy of Medical Science
Qingyuan Zhang
13313612989
sy86298276@163.com
Harbin Medical University Cancer Hospital
Interventions
  • Drug: D-0502 — * Dosage form: Tablet * Administration route: Oral, once a day
  • Drug: Fulvestrant — * Dosage form: Injection * Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose
Study Locations (2 sites)
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing Municipality 100021 China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081 China
Eligibility Criteria
Inclusion Criteria: * Subjects pathologically confirmed with ER-positive, HER2-negative breast cancer; * Subjects with locally advanced (unresectable) or metastatic breast cancer who have disease recurrence during or after adjuvant endocrine therapy, or whose disease has progressed after 1-2 lines of systemic endocrine therapy; * Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria; in the absence of measurable lesions, subjects with evaluable bone lesions \[osteolytic or mixed (osteolytic + osteogenic) bone lesions\] are also acceptable. Lesions that have been previously treated with radiotherapy or other local therapy can be regarded as measurable lesions only if there is disease progression as confirmed by imaging examination; * Expected survival time ≥ 12 weeks; Exclusion Criteria: * Subjects with unstable or symptomatic or progressive central nervous system (CNS) metastases. Subjects with a history of brain metastases who are clinically stable and have no CNS disease progression confirmed by brain MRI or CT (if MRI is not appropriate) can be enrolled (MRI or CT examination must be conducted at least 4 weeks after the last brain radiotherapy); * Subjects with locally advanced or metastatic breast cancer who have previously received more than 2 prior systemic chemotherapy; * Subjects are unsuitable for endocrine therapy judged by the investigator, including uncontrolled pleural effusion, ascites or pericardial effusion; * Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases; * Prior treatment with a selective estrogen receptor degrader (SERD)/selective estrogen receptor covalent antagonist (SERCA), such as fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn -c5, LX-039, HS234, etc.; * Pregnant or lactating females;
Conditions Post Mastectomy Lymphedema
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to determine the combined effect of resisted deep breathing and Myofascial release on pain, respiratory efficiency, chest mobility and lymph edema in Postmastectomy.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Resisted Deep Breathing — The total duration of treatment will be 12 weeks and there will be 2 sessions each week
  • Other: Myofascial release — The total duration of treatment will be 12 weeks and there will be 2 sessions each week

Primary Outcomes

  • Spirometer (12th week)
  • Circumferential limb measurements (12th week)
  • Numerical pain rating scale (NPRS) (12th week)
  • Chest Mobility (12th week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2026-10
Eligibility
Age: 45 Years – 64 Years
Sex: FEMALE
Volunteers: true
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Riphah International University
Principal Investigators:
  • hina gul, PhD* (PRINCIPAL_INVESTIGATOR) - Riphah International University
Contact Information
Study Contact:
imran amjad
03324390125
imran.amjad@riphah.edu.pk
hina gul, PhD*
03214979172
hina.gul@riphah.edu.pk
Riphah medical center
amara eman, MSPT(WH)
Riphah medical center
Interventions
  • Other: Resisted Deep Breathing — The total duration of treatment will be 12 weeks and there will be 2 sessions each week
  • Other: Myofascial release — The total duration of treatment will be 12 weeks and there will be 2 sessions each week
Study Locations (1 sites)
Riphah medical center, Lahore, Punjab Province 6400 Pakistan
Eligibility Criteria
Inclusion Criteria: * Radiation therapy and chemotherapy was finished at least three months * 6 months after mastectomy for breast cancer being diagnosed without lymphedema or with stage 1 lymphedema * Complete unilateral Mastectomy * pain and having one or more of the following symptoms: heaviness, numbness, oppression, stiffness, alterations in the function, or mobility of the limited shoulder range of motion. Exclusion Criteria: * Presence of shoulder pathologies for which surgical indications exist * Musculoskeletal injury in adjacent areas (shoulder or neck etc.) * bilateral surgery for the treatment of breast cancer * Bilateral lymphadenectomy * Open wounds on upper limbs * Circulatory disorders * History of shoulder surgery for reasons other than breast cancer.
Conditions Breast Cancer Females, Insomnia
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if auricular laser acupuncture can improve sleep quality and alleviate related symptoms in female breast cancer patients aged 18 to 75 with insomnia. The main questions it aims to answer are: 1. Does active auricular laser acupuncture improve sleep quality and reduce the severity of insomnia? 2. Does it help lower levels of cancer-related fatigue, anxiety, and depression? Researchers will compare an active auricular laser acupuncture group to a sham control group (receiving no therapeutic laser energy) to see if active laser acupuncture is effective for symptom relief. Participants will: 1. Receive 10 sessions of laser treatment (active or sham) twice a week for 5 weeks, while wearing protective goggles to ensure blinding. 2. Wear an actigraphy wristband and keep a sleep diary to monitor sleep patterns, and undergo heart rate variability (HRV) measurements at baseline and Week 5 (post-treatment). 3. Complete questionnaires assessing sleep, fatigue, mood, and quality of life at baseline, Week 5 (post-treatment), and Week 10 (follow-up).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: auricular laser acupuncture — Using laser pen to stimulation ear acupoint at Shenmen, Subcortex, Heart, Kidney, Occiput, and Sympathetic points, administered for 15 minutes per session, twice weekly, for 5 weeks (10 sessions)
  • Device: sham auricular laser acupuncture — Using laser pen WITH NO LASER OUTPUT to stimulation ear acupoint at Shenmen, Subcortex, Heart, Kidney, Occiput, and Sympathetic points, administered for 15 minutes per session, twice weekly, for 5 weeks (10 sessions)

Primary Outcomes

  • Pittsburgh Sleep Quality Index (PSQI) (base line, 5 weeks (after treatment session))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-26
Completion: 2027-07-31
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: CHING-RONG HUANG
Collaborators: Chung Shan Medical University
Contact Information
Study Contact:
Ching-Rong Huang
+886-4-24739595 #38206
csh.y2080@gmail.com
Ching Rong Huang, Doctor of Medicine (M.D.)
+886-4-24739595 #38206
csh.y2080@gmail.com
Chung Shan Medical University Hospital
Interventions
  • Device: auricular laser acupuncture — Using laser pen to stimulation ear acupoint at Shenmen, Subcortex, Heart, Kidney, Occiput, and Sympathetic points, administered for 15 minutes per session, twice weekly, for 5 weeks (10 sessions)
  • Device: sham auricular laser acupuncture — Using laser pen WITH NO LASER OUTPUT to stimulation ear acupoint at Shenmen, Subcortex, Heart, Kidney, Occiput, and Sympathetic points, administered for 15 minutes per session, twice weekly, for 5 weeks (10 sessions)
Study Locations (1 sites)
Chung Shan Medical University Hospital, Taichung, Taiwan
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 75 years. * Histologically confirmed breast cancer, TNM stage I-III. * Meets the DSM-5 diagnostic criteria for insomnia. * Willing to participate in the study (completion of at least 8 out of 10 treatment sessions). * Able to provide signed informed consent. * No use of sedative-hypnotic medications other than Stilnox, Ativan, Xanax, or Eurodin within the past three months. Exclusion Criteria: * Currently undergoing or planning to undergo chemotherapy, radiotherapy, or surgical treatment during the study period. * Other sleep disorders (e.g., sleep apnea, restless legs syndrome). * Severe physical or psychiatric comorbidities. * Has an implanted cardiac pacemaker. * History of epilepsy. * Taking gametocides or immunosuppressants. * Pregnant. * Substance abuse or alcoholism. * Participated in other clinical trials within the past three months, or concurrent participation during the study period. * Unable to cooperate with the assessment procedures.
Conditions Triple Negative Breast Cancer
Phase PHASE1, PHASE2
Enrollment 220
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: LBL-024 for Injection — Intravenous infusion.
  • Drug: albumin-bound Paclitaxel injection — Intravenous infusion.
  • Drug: Toripalimab Injection — Intravenous infusion.

Primary Outcomes

  • Objective Response Rate (ORR) (From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy))
  • Occurrence of adverse event (AE) and serious adverse event (SAE) (From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy))
  • Progression-free Survival(PFS) (From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-01-27
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 220 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nanjing Leads Biolabs Co.,Ltd
Collaborators: The First Affiliated Hospital with Nanjing Medical University
Principal Investigators:
  • yongmei Yin (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
yongmei Yin
025-83718836
mengdongtao@leadsbiolabs.com
dongtao meng
025-83378099
mengdongtao@leadsbiolabs.com
Sun Yat-sen University Cancer Center
dongtao meng
025-83378099
mengdongtao@leadsbiolabs.com
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Interventions
  • Drug: LBL-024 for Injection — Intravenous infusion.
  • Drug: albumin-bound Paclitaxel injection — Intravenous infusion.
  • Drug: Toripalimab Injection — Intravenous infusion.
Study Locations (7 sites)
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510062 China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510120 China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081 China
Henan Cancer Hospital, Zhengzhou, Henan 450000 China
Jiangsu Province Hospital, Nanjing, Jiangsu 210029 China
The first hospital of Jilin University, Changchun, Jilin 130021 China
Liaoning Cancer Hospital, Shenyang, Liaoning 110000 China
Eligibility Criteria
Inclusion Criteria: 1. Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent. 2. At the time of signing the informed consent form, the age was ≥ 18 years old. 3. The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1. 4. The expected survival time is at least 12 weeks. 5. According to the evaluation of RECIST 1.1 (Response Evaluation Criteria in Solid Tumours),the subjects enrolled have at least one measurable lesion. 6. Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug; Women of childbearing age must have a negative pregnancy test within 7 days before the first trial drug is administered.Male patients are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug,and do not donate sperm during this period. Exclusion Criteria: 1. Use of immunomodulatory drugs within 2 weeks prior to first dose of study drug. 2. Patients who received live vaccination within 4 weeks before the first dose of study drug or who are scheduled to receive live vaccination during the study treatment period and within 4 weeks after the last dose. 3. Patients with clinically uncontrolled pleural effusion, peritoneal effusion, or pericardial effusion. 4. Active infection within 2 weeks prior to first dose of study drug. 5. Active infectious disease. 6. Women with plans for pregnancy,Or women who are pregnant or breastfeeding. 7. Active hepatitis B or active hepatitis C. 8. History of mental illness (interfering with understanding or giving informed consent), drug abuse, alcoholism, or drug addiction. 9. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study. \-
Conditions Triple Negative Breast Cancer, Premenopa...
Phase PHASE2
Enrollment 124
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-15
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer (BC), especially premenopausal, is emerging rapidly in East Asia in recent 20 years. Half of the breast cancer patients in Asia are younger than 50 years of age. In general, younger or premenopausal patients are associated with poorer prognosis. Premenopausal patients have higher estrogen levels than those in older (postmenopausal) patients. Estrogen is known to suppress anti-tumor T cell response and leading to tumor progression in different animal models (Clin Cancer Res 2016 22:6204), including lung cancer, melanoma, ovarian cancer. One of the mechanisms that contributes to estrogen's suppression of T cell function is via the mobilization of myeloid-derived suppressor cells (MDSC). Targeting ER signaling with hormonal therapy can abolish MDSC mobilization, and sensitize tumor cells to antigen specific T cell or NK cell killing (Cancer Discovery 2018 7:72 2017). These study results further support the hypothesis that, E2 is associated with immunosuppressive effect, and may contribute to the suppression of immune surveillance in young female breast cancer patients. These results suggest that E2 may suppress anti-tumor immunity, and E2 reduction improve the anti-tumor immunity. In our preliminary works, the investigators found higher dose (equivalent to premenopausal women serum level) of E2 suppressed T cell activities, while lower dose E2 (postmenopausal serum level) activated T cell activity. The investigators have investigated the combination of anti-PD1 antibody and GnRH agonist plus exemestane (an aromatase inhibitor which will block the production of E2 from adipose tissue) in ER positive premenopausal breast cancer patient refractory to prior endocrine therapy in metastatic setting. The response rate was 38.4%, and median progression-free survival (PFS) was 10.2 months. This outstanding result were presented in AACR 2021 oral session (Cancer Res 2021 81:13\_Supplement, CT028). On the other hand, progesterone is also well known for its anti-inflammation and immune tolerance activity. This possibly makes estrogen reduction treatments, such as gonadotropin-releasing hormone agonist (GnRH agonist), an important partner in augmenting neoadjuvant therapy for patients with premenopausal breast cancer. For triple negative breast cancer (TNBC), endocrine therapy has no anti-tumor effect. On the other hand, the use of GnRH agonist has been tested for the protection of ovary function of young female while receiving adjuvant chemotherapy. Surprisingly, the concomitant use of goserelin and adjuvant chemotherapy improved disease-free survival (HR 0.47, P=0.04) and overall survival (HR 0.45, P=0.05) versus chemotherapy alone in ER negative premenopausal early BC patients in POEMS study, which was initially aimed to improve the success pregnant rate (N Engl J Med 2015 372;923). Endocrine therapy is theoretically antagonist to chemotherapy therapy when concomitantly use. In another report analyzed the outcome of both pre- and…

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg — After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.

Primary Outcomes

  • Pathological complete response rate (During surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-08-22
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Collaborators: Ministry of Health and Welfare, Debiopharm International SA
Contact Information
Study Contact:
Chaio Lo, M.D.
+886-2-23123456
chiaolo@ntuh.gov.tw
Yen-Shen Lu, Ph.D.
+886-2-23123456
yslu@ntu.edu.tw
Chiao Lo, M.D.
+886223123456
chiaolo@ntuh.gov.tw
National Taiwan University Hospital
Interventions
  • Drug: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg — After randomization, patients in the experimental arm (Arm A) will receive GnRH agonist injection within 7 days of randomization and during neoadjuvant chemotherapy treatment. The choice of GnRH agonist, including goserelin, leuprorelin and triptorelin giving in monthly, three-monthly or sixth-monthly, will be made by per investigator's discretion.
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, 100225 Taiwan
Eligibility Criteria
Inclusion Criteria: Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Female patients aged ≥ 18 years at screening; Must be premenopausal according to serum E2, FSH level. 3. Histological confirmed TNBC, as defined by the most recent ASCO/CAP guidelines. Hormone receptor-low/HER2 negative as defined by ER 1% to \<10% and/or PR 1% to \<10% on IHC staining; neither hormone receptor may be ≥ 10%; and HER2-negative (IHC 0+/1+, or IHC 2+ plus FISH negative) is allowed. 4. Have previously untreated locally advanced non-metastatic (M0) TNBC and hormone receptor-low/HER2-negative defined as the following combined primary tumor (T) and regional lymph node (N) staging per current AJCC staging criteria for breast cancer staging criteria as assessed by the investigator based on radiological and/or clinical assessment: T1c, N0-N2; or T2, N0-N2; or T3, N0-N2; or T4a-d, N0-N2. 5. Agree to receive core needle biopsy for translational research. 6. ECOG 0-1. 7. Patients must have adequate organ and marrow reserve measured within 14 days prior to randomization as defined below: * Hemoglobin ≥ 9.0 g/dL; * Absolute neutrophil count ≥ 1,500 /μL; * Platelets ≥ 100,000/μL; * Total bilirubin ≤1.5 x upper normal limit; * AST(SGOT)/ALT(SGPT) ≤ 2.5 x upper normal limit; * Serum creatinine ≤ 1.5mg/dL or creatinine clearance ≧50ml/min; * aPTT \< 1.5 x upper normal limit (unless on therapeutic anti-coagulation); 8. Plan to receive breast cancer surgery. 9. Must have a negative pregnancy test obtained within 3 days before starting therapy. Patients must not be breastfeeding. 10. Patients must use effective contraception prior to study entry and for the duration of study participation, and for 6 months after the completion of therapy. 11. Patients (or a surrogate) must be able to comply with study procedures and to give signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the clinical study protocol (CSP). The patients (or a surrogate) must be able to provide of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses. Exclusion criteria Patients fulfilling any of the following criteria are not eligible for inclusion in this study. No additional exclusions may be applied by the Investigator, in order to ensure that the study population will be representative of all eligible patients. 1. Patients have received any prior therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or hormone therapy) for breast cancer. 2. Evidence of systemic metastasis. 3. Pregnancy or lactation. 4. Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. 5. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs, with exception of hydroxychloroquine (Plaquenil®)) in subjects planning for pembrolizumab use. 6. Has a diagnosis of immunodeficiency or is receiving high dose of systemic steroid therapy. Patients with minor medical disease condition (i.e. mild asthma) requiring prednisolone equal to or less than 20 mg/day or the equivalent may be allowed. 7. Has an active systemic bacterial, viral or fungal infection requiring systemic therapy. 8. Psychiatric illness or social situation that would preclude study compliance. 9. Serious non-healing wound, ulcer, or bone fracture. Except for breast cancer related non-healing wound or ulcer. 10. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrolment. 11. History of allergic reaction to compounds of similar chemical composition to the study drugs. 12. Any of the following conditions or treatments that may impact the safety of the patient: * History of, or current, significant cardiac disease including cardiac failure (NYHA functional class II-IV), myocardial infarction (within 6 months), unstable angina (within 6 months), transient ischemic attack (within 6 months), stroke, cardiac arrhythmias requiring treatment or uncontrolled arterial hypertension * Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker on screening electrocardiogram (ECG) * History of or active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis * Severe hepatic impairment (Child-Pugh class C) * Any medically unstable condition as determined by the Investigator 13. Patients unable or unwilling to undergo serial breast tumor biopsy. 14. History of hypersensitivity to any of the study drugs.